Ligand Pharmaceuticals Inc. (LGND) Partner SAGE Therapeutics Receives Fast Track Designation For Captisol-enabled SAGE-547 To Treat Status Epilepticus
7/23/2014 12:24:03 PM
SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that its partner Sage Therapeutics Inc., a biopharmaceutical company developing novel medicines to treat life-threatening, rare central nervous system (CNS) disorders, announced today that the U.S. Food and Drug Administration (FDA) has granted fast track designation to the SAGE-547 development program. SAGE-547 is an allosteric modulator of GABAA receptors in development for the treatment of adult patients with refractory status epilepticus who have not responded to standard regimens (super-refractory status epilepticus, or SRSE).
Help employers find you! Check out all the jobs and post your resume.
comments powered by